• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Ablation, radiotherapy boost lung cancer patients' survival

Article

Patients with inoperable lung cancer treated with a combination of thermal ablation and radiotherapy were able to add two years to their survival times, according to Brown University Medical School researchers.

Dr. Damian Dupuy, an interventional radiologist at Brown, and colleagues enrolled 41 patients with inoperable stage I/II non-small cell lung cancer tumors who underwent thermal ablation and radiotherapy between 1998 and 2005. The investigators performed 37 radiofrequency and four microwave ablation procedures, followed within 90 days by either external-beam radiotherapy or brachytherapy in 27 and 14 patients, respectively (J Vasc Interv Radiol 2006;17[7]:1117-1124).

None of the patients were expected to live longer than one year, according to the panel of specialists who selected them for the study. The combination therapy, however, prolonged the patients' lives about two years beyond that point.

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.